TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF ACHALASIA
4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS
4.2.3 RISING PUBLIC AWARENESS
4.3 RESTRAINTS
4.3.1 HIGH COST OF TREATMENT
4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS
4.4 OPPORTUNITIES
4.4.1 RISE IN CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON MARKET PLAYERS)
5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION
5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)
5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT
5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:
5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:
5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:
5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:
5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS
6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT
6.1 OVERVIEW
6.2 DIAGNOSIS
6.2.1 ENDOSCOPY
6.2.2 CT SCAN
6.2.3 ESOPHAGRAM
6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)
6.2.5 OTHERS
6.3 TREATMENT
6.3.1 SURGERY
6.3.2 CHEMOTHERAPY
6.3.3 RADIOTHERAPY
6.3.4 IMMUNOTHERAPY
6.3.5 OTHERS
7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER
7.1 OVERVIEW
7.1.1 HOSPITALS
7.1.2 SPECIALTY CENTERS
7.1.3 OTHERS
8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION
8.1 GLOBAL
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 CHINA
8.4.2 INDIA
8.4.3 JAPAN
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
9.6 FINANCIAL MATRIX
9.6.1 SALES (USD MILLION), 2021
9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILES
10.1 F. HOFFMANN-LA ROCHE LTD
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 ASTRAZENECA
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
10.3.1 COMPANY OVERVIEWS
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 SEAGEN INC.
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 ELI LILLY AND COMPANY
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 GLAXOSMITHKLINE PLC
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 NOVARTIS AG
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
LIST OF TABLESTABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 4 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ENDOSCOPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CT SCAN, BY REGION, 2018–2030 (USD MILLION)
TABLE 8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ESOPHAGRAM, BY REGION, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY REGION, 2018–2030 (USD MILLION)
TABLE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2030 (USD MILLION)
TABLE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)
TABLE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR RADIOTHERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR IMMUNOTHERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 17 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 18 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 19 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)
TABLE 20 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 21 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 22 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 23 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 24 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 25 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 26 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 27 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 28 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 29 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 30 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 31 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 32 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 33 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 34 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 35 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 36 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 37 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 38 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 39 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 40 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 41 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 42 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 43 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 44 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 45 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 46 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 47 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 48 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 49 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 50 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 51 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 52 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 53 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 54 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 55 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 56 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 57 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 58 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 59 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 60 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 61 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 62 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 63 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 64 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 65 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 66 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 67 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
TABLE 68 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 74 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 75 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 77 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 78 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 79 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 81 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 82 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 83 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 85 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 86 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 87 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 89 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 90 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 91 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 93 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 94 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 95 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 97 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 98 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 100 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 102 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 103 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 104 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 106 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 107 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 108 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 110 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 111 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 112 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)
TABLE 114 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 115 MAJOR PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
TABLE 116 MOST ACTIVE PLAYER IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
TABLE 117 PRODUCT LAUNCHES/PRODUCT APPROVALS
TABLE 118 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 119 ASTRAZENECA: PRODUCTS OFFERED
TABLE 120 ASTRAZENECA: KEY DEVELOPMENTS
TABLE 121 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 122 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: KEY DEVELOPMENTS
TABLE 123 SEAGEN INC: PRODUCTS OFFERED
TABLE 124 SEAGEN INC.: KEY DEVELOPMENTS
TABLE 125 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 126 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
TABLE 127 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
TABLE 128 NOVARTIS AG: PRODUCTS OFFERED
TABLE 129 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 130 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: PRODUCTS OFFERED
| ※参考情報 食道扁平上皮がんは、食道に発生する悪性腫瘍の一種で、主に食道の内壁を構成する扁平上皮細胞から発生します。このタイプのがんは、特にアジア地域やアフリカなどで高頻度に見られることが特徴です。食道の下部から上部にかけてどこにでも発生する可能性がありますが、特に中部および下部に多く見られます。 このがんは、通常食道の中にある細胞の遺伝子異常によって引き起こされます。喫煙や飲酒、肥満、さらには慢性的な食道炎やバーrett食道などの基礎疾患がリスク因子として知られています。食道扁平上皮がんは、早期には特有の症状が無いため、診断が遅れることがしばしばあります。初期の段階では、嚥下時の違和感や軽度の痛みを感じることがありますが、進行すると体重減少や胸痛、飲み込みにくさといった症状が現れます。 食道扁平上皮がんにはいくつかの種類があり、その病理分類にはさまざまな組織学的特徴が存在します。腫瘍のグレードは、細胞の分化度によって「高分化型」「中分化型」「低分化型」に分類され、それぞれの型によって予後や治療法が異なることがあります。一般的に、高分化型のがんは予後が良好で、低分化型は進行が早く、治療が困難になる傾向があります。 治療方法は病期や患者の全体的な健康状態によって異なりますが、一般的には外科手術、放射線療法、化学療法などが行われます。早期の場合は、腫瘍の切除が目的となることが多いですが、進行したがんの場合は、化学療法や放射線療法が併用されることが一般的です。緩和ケアも重要で、特に進行がんの場合には、症状の軽減を目的としたケアが重視されます。 最近の技術は、食道扁平上皮がんの早期診断と治療に貢献しています。内視鏡による診断技術が高度化し、細胞診や組織検査を通じて早期にがんを発見することが可能になりました。さらに、新しい薬剤や治療法の開発も進んでおり、特に分子標的治療や免疫療法が注目されています。これにより、より個別化された治療が可能となり、患者の生存率向上が期待されています。 食道扁平上皮がんに関する研究は日々進展しており、遺伝子解析やバイオマーカーの研究など新しいアプローチが模索されています。これにより、診断能や治療効果の向上が図られることが期待されています。 以上のように、食道扁平上皮がんは重要な疾患であり、その治療や早期発見に向けた取り組みが絶えず行われています。この病気に対する理解が深まり、適切な予防法や治療法が広まることが、今後の課題となるでしょう。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
